Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

Dendrimeric antigens for passive mast cell activation in the evaluation of amoxicillin allergy

  • Tesfaye Ayane, Amene
  • Salas, María
  • Benede, Sara
  • Rodríguez-Sánchez, Maria J.
  • Rodríguez-Sojo, María J.
  • Jiménez-Sánchez, Isabel M.
  • Bogas, Gador
  • Pérez-de-Inestrosa-Villatoro, Ezequiel
  • Mayorga, Cristobalina
  • Paris, Juan L.
  • Rodríguez-Nogales, Alba
  • Torres-Jaén, María Josefa
  • Montañez-Vega, María Isabel
Background: Amoxicillin (AX) is frequently implicated in immediate IgE-mediated allergic reactions. Diagnosis is challenging,highlighting the need for new approaches enhancing in vitro sensitivity and specificity. Engineered nanostructures can mimicimmunological recognition of hapten-carrier conjugates, offering a strategy to improve diagnostic accuracy.Methods: Dendrimeric Antigens (DeAns), with controlled size (1st–5th generation) and multivalent AX determinants (8–128 units, respectively), were synthesized for in vitro immunological evaluation. In vitro IgE recognition was studied by com-petitive radio-immunoassay. Allergenic activity was evaluated in mouse bone marrow-derived mast cells (MC) sensitized withmouse anti-AX IgE monoclonal antibody and humanized RBL-2H3 (huRBL-2H3) and LUVA cells sensitized with sera fromβ-lactam-allergic subjects and tolerant controls, measuring degranulation in response to DeAns stimulation.Results: Five different DeAns were obtained as pure compounds. All DeAns were recognized by AX-sIgE. A clear size-dependent activation pattern was observed in the three cell models: lower-generation (1st–2nd) DeAns failed to induce degranu-lation, whereas DeAns of bigger size (3rd–5th generation) triggered significant, dose-dependent activation. Notably, no activationwas observed in tolerants and unsensitized cells or with blank dendrimers. In patient-sera assays, the passive MC activation test(pMAT) with DeAns provided complete diagnostic discrimination, with activation restricted to AX-allergic patients.Conclusions: DeAns are effective platforms for investigating effector cell activation in AX allergy. By fine-tuning structuralattributes—size and multivalence—we reveal the promising utility of DeAns in pMAT that leverage commercial cell lines andpatient sera. This approach could address key limitations of β-lactam allergy diagnostics, enabling more reliable and standard-ized in vitro testing., Funding for open access charge: Universidad de Málaga / CBUA
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Extracellular vesicle-based therapeutics for heart repair

  • Saludas, Laura
  • Oliveira, Cláudia C.
  • Roncal Mancho, Carmen
  • Ruiz-Villalba, Adrián
  • Prósper, Felipe
  • Garbayo, Elisa
  • Blanco-Prieto, María J.
Extracellular vesicles (EVs) are constituted by a group of heterogeneous membrane vesicles secreted by most cell types that play a crucial role in cell¿cell communication. In recent years, EVs have been postulated as a relevant novel therapeutic option for cardiovascular diseases, including myocardial infarction (MI), partially outperforming cell therapy. EVs may present several desirable features, such as no tumorigenicity, low immunogenic potential, high stability, and fine cardiac reparative efficacy. Furthermore, the natural origin of EVs makes them exceptional vehicles for drug delivery. EVs may overcome many of the limitations associated with current drug delivery systems (DDS), as they can travel long distances in body fluids, cross biological barriers, and deliver their cargo to recipient cells, among others. Here, we provide an overview of the most recent discoveries regarding the therapeutic potential of EVs for addressing cardiac damage after MI. In addition, we review the use of bioengineered EVs for targeted cardiac delivery and present some recent advances for exploiting EVs as DDS. Finally, we also discuss some of the most crucial aspects that should be addressed before a widespread translation to the clinical arena., This work was funded by Spanish Ministry of Economy and Competitiveness (SAF2017-83734-R), the 7th EuroNanoMed-II call for proposals, project NanoHeart n°ANR-16-ENM2-0005-01 and Nano ReHeart AC15/0050. C.O. is supported by the European Union‘s Horizon 2020 research and innovation programme Under the Marie Sklodowska-Curie grant agreement No 713721. A.R.V. was supported by a Juan de La Cierva Fellowship (IJCI-2016-30254) and is supported by a “I Plan Propio de Incorporación de Doctores” from the University of Málaga, and by the Spanish Ministerio de Ciencia y Universidades (RTI2018-095410-B-I00). E. Garbayo is supported by a “Ramon y Cajal Fellowship” (RYC2018-025897-I).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Optimizing the limit of detection of waveguide-based interferometric biosensor devices

  • Leuermann, Jonas
  • Fernández Gavela, Adrián
  • Torres Cubillo, Antonia
  • Postigo, Sergio
  • Sánchez Postigo, Alejandro
  • Lechuga, Laura M.
  • Halir, Robert
  • Molina Fernández, Íñigo
This article belongs to the Special Issue Waveguide-Based Sensors., Waveguide-based photonic sensors provide a unique combination of high sensitivity, compact size and label-free, multiplexed operation. Interferometric configurations furthermore enable a simple, fixed-wavelength read-out making them particularly suitable for low-cost diagnostic and monitoring devices. Their limit of detection, i.e., the lowest analyte concentration that can be reliably observed, mainly depends on the sensors response to small refractive index changes, and the noise in the read-out system. While enhancements in the sensors response have been extensively studied, noise optimization has received much less attention. Here we show that order-of-magnitude enhancements in the limit of detection can be achieved through systematic noise reduction, and demonstrate a limit of detection of ∼ 10−8RIU with a silicon nitride sensor operating at telecom wavelengths., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 713721. We would like to acknowledge the Ministerio de Economía y Competitividad, Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (cofinanciado FEDER), Proyecto TEC2016-80718-R, and the Universidad de Málaga. Proyecto I+D+i en el marco del Programa Operativo FEDER Andalucía 2014-2020 (UMA18-FEDERJA-219). ICN2 is supported by the Severo Ochoa program from Spanish MINECO (Grant No. SEV-2017-0706), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Coherent silicon photonic interferometric biosensor with an inexpensive laser source for sensitive label-free immunoassays

  • Leuermann, Jonas
  • Stamenkovic, Vladimir
  • Ramirez-Priego, Patricia
  • Sánchez Postigo, Alejandro
  • Fernández Gavela, Adrián
  • Chapman, Cole A.
  • Bailey, Ryan C.
  • Lechuga, Laura M.
  • Pérez-Inestrosa, Ezequiel
  • Collado, Daniel
  • Halir, Robert
  • Molina Fernández, Íñigo
Over the past two decades, integrated photonic sensors have been of major interest to the optical biosensor community due to their capability to detect low concentrations of molecules with label-free operation. Among these, interferometric sensors can be read-out with simple, fixed-wavelength laser sources and offer excellent detection limits but can suffer from sensitivity fading when not tuned to their quadrature point. Recently, coherently detected sensors were demonstrated as an attractive alternative to overcome this limitation. Here we show, for the first time, to the best of our knowledge, that this coherent scheme provides sub-nanogram per milliliter limits of detection in C-reactive protein immunoassays and that quasi-balanced optical arm lengths enable operation with inexpensive Fabry–Perot-type lasers sources at telecom wavelengths., Horizon 2020 Framework Programme (EuroNanoMed 3-H2020 DrNanoDAII); Ministerio de Economía y Competitividad (2019/PCI 2019-2, CTQ2017-86994-R, SEV-2017-0706); Junta de Andalucía, Proyectos Excelencia-Retos (P18-RT-1453, P18-RT-793); Fondos Europeos de Desarrollo Regional (CTQ2016-75870-P, PID2019-104293GB-I00, RD16/0006/0012, TEC2016-80718-R, UMA18-FEDERJA-007, UMA18-FEDERJA-219); H2020 Marie Skłodowska-Curie Actions (713721)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy

  • Tesfaye, Amene
  • Rodríguez-Nogales, Alba
  • Benedé, Sara
  • Fernández, Tahia
  • Paris, Juan L.
  • Rodriguez, Maria J.
  • Jiménez-Sánchez, Isabel M.
  • Bogas, Gador
  • Mayorga, Cristobalina
  • Torres, María J.
  • Montañez, M. I.
[Background]: Amoxicillin (AX) is nowadays the β-lactam that more frequently induces immediate allergic reactions. Nevertheless, diagnosis of AX allergy is occasionally challenging due to risky in vivo tests and non-optimal sensitivity of in vitro tests. AX requires protein haptenation to form multivalent conjugates with increased size to be immunogenic. Knowing adduct structural features for promoting effector cell activation would help to improve in vitro tests. We aimed to identify the optimal structural requirement in specific cellular degranulation to AX using well-precised nanoarchitectures of different lengths., [Method]: We constructed eight Bidendron Antigens (BiAns) based on polyethylene glycol (PEG) linkers of different lengths (600–12,000 Da), end-coupled with polyamidoamine dendrons that were terminally multi-functionalized with amoxicilloyl (AXO). In vitro IgE recognition was studied by competitive radioallergosorbent test (RAST) and antibody–nanoarchitecture complexes by transmission electron microscopy (TEM). Their allergenic activity was evaluated using bone marrow-derived mast cells (MCs) passively sensitized with mouse monoclonal IgE against AX and humanized RBL-2H3 cells sensitized with polyclonal antibodies from sera of AX-allergic patients., [Results]: All BiAns were recognized by AX-sIgE. Dose-dependent activation responses were observed in both cellular assays, only with longer structures, containing spacers in the range of PEG 6000–12,000 Da. Consistently, greater proportion of immunocomplexes and number of antibodies per complex for longer BiAns were visualized by TEM., [Conclusions]: BiAns are valuable platforms to study the mechanism of effector cell activation. These nanomolecular tools have demonstrated the importance of the adduct size to promote effector cell activation in AX allergy, which will impact for improving in vitro diagnostics., The present study was supported by the Institute of Health “Carlos III” (ISCIII) of MINECO (grants cofunded by ERDF: “Una manera de hacer Europa” (grant numbers PI12/02529, PI15/01206, CP15/00103, PI17/01237, PI18/00095, PI20/01734, PI20/01447, RETICS ARADYAL RD16/0006/0001, Euronanomed Program AC19/00082); Andalusian Regional Ministry of Economy and Knowledge (grants cofunded by ERDF: “Andalucía se mueve con Europa”: grant no. CTS-06603); Andalusian Regional Ministry of Health (grant nos PI-0699-2011, PI-0179-2014); and “Premio UNICAJA a la innovación en biomedicina y salud.” AT has received funding from the European Union’s H2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 713721). S.B. acknowledges financial support of Ministerio de Ciencia, Innovación y Universidades from Spain through a Juan de la Cierva Incorporación contract. C.M. holds “Nicolas Monardes” research contract by Andalusian Regional Ministry Health (grant no. RC-0004-2021). G.B. holds a “Juan Rodes” grant (JR18/00054), J.L.P holds a “Sara Borrell” grant (CD19/00250), A.R.N. and M.I.M. hold a “Miguel Servet I” grant (CP19/00191 and CP15/00103), both grants cofunded by European Social Fund (“El FSE invierte en futuro”). Tesfaye reports grants from Marie Skłodowska-Curie [grant No 713721], during the conduct of the study; in addition, Tesfaye has a patent PCT/ES2021/070103 pending. Dr. RODRIGUEZ NOGALES reports grants from ISCIII, during the conduct of the study; in addition, Dr. RODRIGUEZ NOGALES has a patent PCT/ES2021/070103 pending. Dr. Benede reports grants from Ministerio de Ciencia, Innovación y Universidades, during the conduct of the study. Dr. Fernandez reports grants from ISCIII, during the conduct of the study; In addition, Dr. Fernandez has a patent PCT/ES2021/070103 pending. Dr. Paris reports a Sara Borrell fellowship from ISCIII (CD19/00250), cofunded by European Social Fund. Dr. Rodriguez reports grants from ISCIII, during the conduct of the study. JIMÉNEZ-SÁNCHEZ reports grants from MICIN (PEJ2018-002865-A), during the conduct of the study; Dr. BOGAS HERRERA reports grants from ISCIII, during the conduct of the study. Dr. Mayorga reports grants from ISCIII, from Andalusian Regional Ministry Health, during the conduct of the study; in addition, Dr. Mayorga has a patent PCT/ES2021/070103 pending. Dr. Torres reports grants from ISCIII, during the conduct of the study; in addition, Dr. Torres has a patent PCT/ES2021/070103 pending. Dr. Montañez reports grants from ISCIII, during the conduct of the study; in addition, Dr. Montañez has a patent PCT/ES2021/070103 pending., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Optimizing the limit of detection of waveguide-based interferometric biosensor devices

  • Leuermann, Jonas|||0000-0001-7321-5190
  • Fernandez-Gavela, Adrian|||0000-0002-4562-1308
  • Torres Cubillo, Antonia
  • Postigo, Sergio
  • Sánchez-Postigo, Alejandro|||0000-0003-4782-0105
  • Lechuga, Laura M.|||0000-0001-5187-5358
  • Halir, Robert|||0000-0002-5560-3189
  • Molina-Fernandez, Iñigo|||0000-0001-9596-4117
Waveguide-based photonic sensors provide a unique combination of high sensitivity, compact size and label-free, multiplexed operation. Interferometric configurations furthermore enable a simple, fixed-wavelength read-out making them particularly suitable for low-cost diagnostic and monitoring devices. Their limit of detection, i.e., the lowest analyte concentration that can be reliably observed, mainly depends on the sensors response to small refractive index changes, and the noise in the read-out system. While enhancements in the sensors response have been extensively studied, noise optimization has received much less attention. Here we show that order-of-magnitude enhancements in the limit of detection can be achieved through systematic noise reduction, and demonstrate a limit of detection of ~10 RIU with a silicon nitride sensor operating at telecom wavelengths.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Coherent silicon photonic interferometric biosensor with an inexpensive laser source for sensitive label-free immunoassays

  • Leuermann, Jonas|||0000-0001-7321-5190
  • Stamenkovic, Vladimir
  • Ramirez Priego, Patricia|||0000-0001-5657-3279
  • Sánchez-Postigo, Alejandro|||0000-0003-4782-0105
  • Fernandez-Gavela, Adrian|||0000-0002-4562-1308
  • Chapman, Cole A.
  • Bailey, Ryan C.
  • Lechuga, Laura M.|||0000-0001-5187-5358
  • Pérez Inestrosa, Ezequiel|||0000-0001-7546-5273
  • Collado, Daniel
  • Halir, Robert|||0000-0002-5560-3189
  • Molina-Fernandez, Iñigo|||0000-0001-9596-4117
Over the past two decades, integrated photonic sensors have been of major interest to the optical biosensor community due to their capability to detect low concentrations of molecules with label-free operation. Among these, interferometric sensors can be read-out with simple, fixed-wavelength laser sources and offer excellent detection limits but can suffer from sensitivity fading when not tuned to their quadrature point. Recently, coherently detected sensors were demonstrated as an attractive alternative to overcome this limitation. Here we show, for the first time, to the best of our knowledge, that this coherent scheme provides sub-nanogram per milliliter limits of detection in C-reactive protein immunoassays and that quasi-balanced optical arm lengths enable operation with inexpensive Fabry-Perot-type lasers sources at telecom wavelengths.
Dipòsit Digital de Documents de la UAB
Publicación Capítulo o parte de un libro (BookPart)

Silicon photonic label free biosensors with coherent readout

  • Leuermann, Jonas|||0000-0001-7321-5190
  • Fernandez-Gavela, Adrian|||0000-0002-4562-1308
  • Halir, Robert|||0000-0002-5560-3189
  • Ortega-Monux, Alejandro|||0000-0001-8313-6381
  • Wangüemert-Pérez, J.G.
  • Lechuga, Laura M.|||0000-0001-5187-5358
  • Molina-Fernandez, Iñigo|||0000-0001-9596-4117
Silicon photonics enables sensitive and label-free optical biosensors for the detection of chemical and biological substances. Different sensing architectures have been used to improve the limit of detection and increase the dynamic range response. Here, we show experimental limit of detection at state-of-the-art level using silicon nitride integrated Mach-Zehnder interferometers with coherent read-out. These preliminary results are concordant with theoretical results, showing that the proposed approach enables the use of simple read-out equipment using low-cost laser sources.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Coherent silicon photonic interferometric biosensor with an inexpensive laser source for sensitive label-free immunoassays

  • Leuermann, J.
  • Stamenkovic, V.
  • Ramírez Priego, P.
  • Sánchez Postigo, A.
  • Fernández Gavela, Adrián|||0000-0002-4562-1308
  • Chapman, C. A.
  • Bailey, R. C.
  • Lechuga, L. M.
  • Pérez Inestrosa, E.
  • Collado, D.
  • Halir, R.
  • Molina Fernández, I.
Horizon 2020 Framework Programme (EuroNanoMed 3-H2020 DrNanoDAII); Ministerio de Economía y Competitividad (2019/PCI 2019-2, CTQ2017-86994-R, SEV-2017-0706); Junta de Andalucía, Proyectos Excelencia-Retos (P18-RT-1453, P18-RT-793); Fondos Europeos de Desarrollo Regional (CTQ2016-75870-P, PID2019-104293GBI00, RD16/0006/0012, TEC2016-80718-R, UMA18-FEDERJA-007, UMA18-FEDERJA-219); H2020 Marie Skłodowska-Curie Actions (713721).